ResMed (RMD) Stock Analysis & AI Equity Report

Medical - Equipment & Services USD Explore free reports

ResMed (RMD) overview

ResMed (RMD) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 5,653m and operating profit of USD 1,887m; the year-end share price was 194.88 USD and market capitalisation was USD 28,109m. ResMed is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ResMed's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 6,585mFY 2026
Share price194.88 USDFY 2026 year end
RevenueUSD 5,653mFY 2026
Operating profitUSD 1,887mFY 2026
Net earningsUSD 1,523mFY 2026
Market capitalisationUSD 28,109mFY 2026 year end

About ResMed

ResMed develops digital health solutions and cloud-connected medical devices for sleep and breathing disorders and related conditions. Its offerings include CPAP systems, ventilation and life-support devices, diagnostic products, masks, accessories, dental devices, and cloud-based applications and software for connected care. The company also provides in-home testing services and management software. Its customers include patients, clinicians, home medical equipment providers, and residential care providers.

Generate the ResMed report

ResMed is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for ResMed and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on ResMed

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.